Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC

Delayed Quote. Delayed  - 05/27 09:59:48 pm
0.4 USD   -6.69%
05/28 CYCLACEL PHARMA : Announces Reverse Stock Split
05/27 Cyclacel Announces Reverse Stock Split
05/19 CYCLACEL PHARMA : Seliciclib-Sapacitabine Abstract Selected for Oral..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2016 05/24/2016 05/25/2016 05/26/2016 05/27/2016 Date
0.345(c) 0.38(c) 0.43(c) 0.4287(c) 0.42(c) Last
190 531 104 449 432 380 56 895 149 106 Volume
-3.82% +10.14% +13.16% -0.30% -2.03% Change
More quotes
Financials ($)
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
05/28 CYCLACEL PHARMACEUTICALS : Announces Reverse Stock Split
05/27 CYCLACEL PHARMACEUTICALS, INC. : Material Modification to Rights of Security Hol..
05/27 Cyclacel Announces Reverse Stock Split
05/19 CYCLACEL PHARMACEUTICALS : Seliciclib-Sapacitabine Abstract Selected for Oral Pr..
05/19 Cyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentat..
05/11 Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
05/04 Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
04/19 CYCLACEL PHARMACEUTICALS : Cyclacels Second-Generation CDK2/9 Inhibitor, CYC065,..
04/18 CYCLACEL PHARMACEUTICALS : Second-Generation CDK2/9 Inhibitor, CYC065, is an Eff..
04/18 Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective ..
More news
Sector news : Bio Therapeutic Drugs
05/30 Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collabo..
05/30 GENMAB A/S : Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collab..
05/30 Samsung Bioepis receives final European approval for its Remicade copy
05/27 AMGEN : receives positive CHMP opinion to extend indication of Kyprolis
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Pos..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/27 CYCLACEL PHARMA REVERSE SPLITS STOCK : 12 effective today, post-split trading co..
05/12 Cyclacel Pharmaceuticals reports Q1 results
05/11 Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2016 Results - Earn..
05/11 Cyclacel Pharmaceuticals reports Q1 results
03/24 Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q4 2015 Results - Earn..
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | CYCC | US23254L3069 | 4-Traders
Full-screen chart
Technical analysis trends CYCLACEL PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions